Azoy Alexander 4
4 · Arcus Biosciences, Inc. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Azoy Alexander
Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-26$13.33/sh+1,900$25,327→ 29,263 total - Sale
Common Stock
2025-11-26$26.00/sh−1,900$49,400→ 27,363 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-26−1,900→ 9,500 totalExercise: $13.33Exp: 2035-01-22→ Common Stock (1,900 underlying)
Footnotes (2)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company.